​

Corcept Therapeutics (CORT) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

CORT Stock Forecast

Corcept Therapeutics (CORT) stock forecast, based on 25 Wall Street analysts, predicts a 12-month average price target of $71.67, with a high of $100.00 and a low of $30.00. This represents a 54.06% increase from the last price of $46.52.

$20 $36 $52 $68 $84 $100 High: $100 Avg: $71.67 Low: $30 Last Closed Price: $46.52

CORT Stock Rating

Corcept Therapeutics stock's rating consensus is Buy, based on 25 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 13 Buy (52.00%), 10 Hold (40.00%), 2 Sell (8.00%), and 0 Strong Sell (0.00%).

Buy
Total 25 0 2 10 13 Strong Sell Sell Hold Buy Strong Buy

CORT Price Target Upside V Benchmarks

TypeNameUpside
StockCorcept Therapeutics54.06%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts1212
Avg Price Target$88.00$77.50$95.33
Last Closing Price$46.52$46.52$46.52
Upside/Downside89.17%66.60%104.92%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 26132--6
Mar, 261311-6
Feb, 261311-6
Jan, 261311-6
Dec, 25131--5
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
May 01, 2026Piper Sandler$88.00$46.5289.17%89.17%
Feb 20, 2026H.C. Wainwright$67.00$34.2495.68%44.02%
Jan 23, 2026Canaccord Genuity$100.00$41.30142.13%114.96%
Jan 22, 2026Swayampakula RamakanthH.C. Wainwright$105.00$41.47153.20%125.71%
Jan 02, 2026Swayampakula RamakanthH.C. Wainwright$90.00$36.35147.59%93.47%
Jan 02, 2026Edward NashCanaccord Genuity$99.00$36.90168.29%112.81%
Dec 31, 2025Truist Financial$50.00$34.2545.99%7.48%
Dec 31, 2025Wolfe Research$30.00$33.12-9.42%-35.51%
Dec 16, 2025Ashwani VermaUBS$95.00$87.308.82%104.21%
Sep 10, 2025Canaccord Genuity$140.00$71.6295.48%200.95%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
May 01, 2026Piper SandlerOverweightOverweighthold
Mar 26, 2026Wolfe ResearchUnderperformPeer Performupgrade
Jan 22, 2026H.C. WainwrightBuyBuyhold
Jan 02, 2026Canaccord GenuityBuyBuyhold
Jan 02, 2026H.C. WainwrightBuyBuyhold
Dec 31, 2025Wolfe ResearchUnderperformdowngrade
Dec 16, 2025UBSNeutralinitialise
May 06, 2025H.C. WainwrightBuyBuyhold
Oct 18, 2024Sandler O'NeillBuyBuyhold
Oct 18, 2024H.C. WainwrightBuyBuyhold

Financial Forecast

EPS Forecast

$0 $1 $2 $3 $4 $5 $6 $7 $8 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$0.97$0.95$1.02$1.35$0.95---
Avg Forecast$0.89$0.96$0.92$1.36$1.91$3.20$4.85$6.86
High Forecast$0.94$1.01$0.94$1.45$2.66$3.67$6.54$7.21
Low Forecast$0.85$0.91$0.88$1.27$1.41$2.39$3.23$6.59
Surprise %8.99%-1.04%10.87%-0.74%-50.26%---

Revenue Forecast

$0 $400M $800M $1B $2B $2B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$365.98M$401.86M$482.38M$675.04M$761.41M---
Avg Forecast$367.75M$403.88M$476.28M$691.84M$810.08M$1.04B$1.32B$1.66B
High Forecast$381.81M$421.56M$495.04M$703.42M$836.21M$1.04B$1.32B$1.73B
Low Forecast$353.89M$389.49M$461.63M$684.53M$792.21M$1.04B$1.32B$1.61B
Surprise %-0.48%-0.50%1.28%-2.43%-6.01%---

Net Income Forecast

$50M $210M $370M $530M $690M $850M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$112.51M$101.42M$106.14M$139.73M$98.17M---
Avg Forecast$90.08M$107.54M$105.50M$151.97M$201.37M$395.01M$603.99M$766.55M
High Forecast$108.10M$129.05M$126.60M$162.10M$297.40M$410.27M$730.61M$805.80M
Low Forecast$72.07M$86.03M$84.40M$141.84M$157.99M$267.18M$360.84M$735.89M
Surprise %24.90%-5.69%0.61%-8.05%-51.25%---

CORT Forecast FAQ

Is Corcept Therapeutics stock a buy?

Corcept Therapeutics stock has a consensus rating of Buy, based on 25 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 13 Buy, 10 Hold, 2 Sell, and 0 Strong Sell, reflecting a consensus that Corcept Therapeutics is a favorable investment for most analysts.

What is Corcept Therapeutics's price target?

Corcept Therapeutics's price target, set by 25 Wall Street analysts, averages $71.67 over the next 12 months. The price target range spans from $30 at the low end to $100 at the high end, suggesting a potential 54.06% change from the previous closing price of $46.52.

How does Corcept Therapeutics stock forecast compare to its benchmarks?

Corcept Therapeutics's stock forecast shows a 54.06% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Corcept Therapeutics over the past three months?

  • April 2026: 16.67% Strong Buy, 50.00% Buy, 33.33% Hold, 0% Sell, 0% Strong Sell.
  • March 2026: 16.67% Strong Buy, 50.00% Buy, 16.67% Hold, 16.67% Sell, 0% Strong Sell.
  • February 2026: 16.67% Strong Buy, 50.00% Buy, 16.67% Hold, 16.67% Sell, 0% Strong Sell.

What is Corcept Therapeutics’s EPS forecast?

Corcept Therapeutics's average annual EPS forecast for its fiscal year ending in December 2026 is $3.2, marking a 236.84% increase from the reported $0.95 in 2025. Estimates for the following years are $4.85 in 2027, and $6.86 in 2028.

What is Corcept Therapeutics’s revenue forecast?

Corcept Therapeutics's average annual revenue forecast for its fiscal year ending in December 2026 is $1.04B, reflecting a 36.83% increase from the reported $761.41M in 2025. The forecast for 2027 is $1.32B, and $1.66B for 2028.

What is Corcept Therapeutics’s net income forecast?

Corcept Therapeutics's net income forecast for the fiscal year ending in December 2026 stands at $395.01M, representing an 302.37% increase from the reported $98.17M in 2025. Projections indicate $603.99M in 2027, and $766.55M in 2028.